Angiogenesis-dependent diseases

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 536-542

  Folkman, J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CHLOROQUINE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; MACRONEX 160; MEPACRINE; MESSENGER RNA; PENTOXIFYLLINE; ROLIPRAM; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER RESEARCH; DRUG EFFICACY; DRUG RESEARCH; HUMAN; LEUKEMIA; MICROVASCULATURE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VASCULARIZATION;

EID: 0035211504     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90021-1     Document Type: Article

References (42)

1. Tumor angiogenesis
2. Angiogenesis
3. Regulation of angiogenesis
4. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
5. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
6. Bone marrow angiogenesis and progression in multiple myeloma
7. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
8. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
9. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion, parallel progression of human multiple myeloma
10. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies
11. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
12. Angiogenesis research: Guidelines for translation to clinical application
13. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
14. Prognostic value of bone marrow angiogenesis in multiple myeloma
15. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
16. 42nd annual meeting of the American Society of Hematology
17. Vascular density, intracellular VEGFand bFGF positivity as prognostic factors in polycythemia vera and chronic myelocytic leukemia
18. Tumor angiogenesis: Therapeutic implications
19. Tumor growth and neovascularization: An experimental model using rabbit cornea
20. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
21. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
22. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
23. Thalidomide is an inhibitor of angiogenesis
24. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
25. Antitumor activity of thalidomide in refractory multiple myeloma
26. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
27. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
28. Thalidomide in the treatment of relapsed multiple myeloma
29. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
30. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM)
31. Low-dose of thalidomide in the treatment of refractory myeloma
32. Angiogenesis in hematologic malignancies with focus on multiple myeloma
33. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
34. Thalidomide-A revival story
35. Hypoxic induction of endothelial cell growth factors in retinal identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen
36. The von Hippel-Lindau tumor suppressor gene
37. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
38. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
39. Antiangiogenic therapy of haemangiomas with interferon A
40. Antiangiogenic and antitumor activities of cyclooxygenase- 2 inhibitors
41. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
42. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis